Next Article in Journal
Previous Article in Journal
Short Note

Diethyl 4-(6-Chloroimidazo[2,1-b]thiazol-5-yl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate and Ethyl 4-(6-Chloroimidazo[2,1-b]thiazol-5-yl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate

Department of Pharmacy and Biotechnologies FaBiT, University of Bologna, via Belmeloro 6, 40126 Bologna, Italy
Author to whom correspondence should be addressed.
Molbank 2012, 2012(4), M787;
Received: 30 October 2012 / Accepted: 15 November 2012 / Published: 20 November 2012


Diethyl 4-(6-chloroimidazo[2,1-b]thiazol-5-yl)-2,6-dimethyl-1,4-dihydropyridine- 3,5-dicarboxylate and ethyl 4-(6-chloroimidazo[2,1-b]thiazol-5-yl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate were obtained simultaneously by the Biginelli reaction using a green protocol and curtailing reaction time.
Keywords: 3,4-dihydropyrimidin-2(1H)-ones; 1,4-dihydropyridines; imidazo[2,1-b]thiazole 3,4-dihydropyrimidin-2(1H)-ones; 1,4-dihydropyridines; imidazo[2,1-b]thiazole
Molecular scaffolds such as 3,4-dihydropyrimidin-2(1H)-ones (DHPMs), synthesized the first time by Biginelli reaction [1], fascinated both biologists and medicinal chemists for their polyhedral pharmacological worth and the synthetic challenge to improve reaction conditions and yields. DHPMs motifs appropriately decorated, as far as 1,4-dihydropyridines (1,4-DHPs), play a role in a large range of activities: antitumor [2], antihypertensive [3], antitubercular [4]. Interestingly, the imidazo[2,1-b]thiazole is a well-known system able to endow 1,4-DHPs specific activities such as the cardiovascular [5] one. Moreover, 3,4-DHPMs bearing an imidazo[2,1-b]thiazole system are still unknown in literature and they could show new and interesting activities. For these reasons, we focused our study on the synthesis of a library of 3,4-DHPMs and 1,4-DHPs bearing an imidazo[2,1-b]thiazole system, using a Biginelli reaction protocol [6]. This procedure is green, fast, cheap to apply and assures the simultaneous production of both 1,4-DHPs and 3,4-DHPMs by means of a one-pot system. The present paper reports the synthesis of compounds 2 and 3 (see Scheme 1).
The aldehyde 1 was synthesized by Vilsmeier formylation of the imidazo[2,1-b]thiazole scaffold as previously described [7], then compound 1 was submitted to the Biginelli cyclocondensation, applying a method reported by Ranu et al. [6] (Scheme 1) and modified to be suitable for the imidazo[2,1-b]thiazole moiety.
Scheme 1. Synthesis of the title compounds 2 and 3.
Scheme 1. Synthesis of the title compounds 2 and 3.
Molbank 2012 m787 sch001



The melting points are uncorrected. TLC analysis were performed on Bakerflex plates (silica gel IB2-F). Kieselgel 60 (VWR, Milan, Italy) was used for flash chromatography. The IR spectra were recorded in nujol on a Nicolet Avatar 320 E.S.P.; νmax are expressed in cm−1. The 1H-NMR and 13C-NMR spectra were recorded in DMSO-d6 on a Varian MR 400 MHz (ATB PFG probe); the chemical shifts (referenced to solvent signal) are expressed in ppm (δ) and J in Hz (abbreviations: th = thiazole, py = pyridine, pym = pyrimidinone). Urea and ethyl acetoacetate were purchased from Sigma Aldrich and were used as delivered without further purification, whereas aldehyde 1 was prepared according to the literature [7].

Diethyl 4-(6-Chloroimidazo[2,1-b]thiazol-5-yl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate (2), Ethyl 4-(6-Chloroimidazo[2,1-b]thiazol-5-yl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate (3)

Aldehyde 1 (2 g, 0.01 mol) was mixed homogeneously with ethyl acetoacetate (1.4 mL, 0.01 mol) and urea (0.96 g, 0.01 mol). The mixture was stirred at 125–130 °C for two hours according to a TLC test, the eluent was a mixture of dichloromethane/ethanol 9:1. Afterwards, the mixture was allowed to cool at room temperature. The black fused solid obtained was grinded to get a powder, added to hot water (30 mL) and filtered off by suction. The washed powder was then purified by flash chromatography eluting with a gradient of acetone/petroleum ether from 0:1 to 6:4, v/v. After separation, a yellow solid and an orange powder were obtained, corresponding to analytically pure samples of compounds 2 (yield 15%) and 3 (yield 45%) respectively.

Data for Compound 2

M.p.: 165 °C.
IR (nujol, cm−1): 1653, 1458, 1377, 1272, 1160.
1H-NMR (400 MHz, DMSO-d6) δ (ppm): 0.97 (6H, t, COOCH2CH3, J = 7.2), 2.25 (6H, s, CH3), 3.91 (4H, m, COOCH2CH3), 5.20 (1H, s, py), 7.32 (1H, d, th, J = 4.8), 7.77 (1H, d, th, J = 4.8), 9.04 (1H, s, NH).
13C-NMR (400 MHz, DMSO-d6) δ (ppm): 14.99, 18.87, 31.47, 60.03, 98.22, 113.09, 120.88, 129.20, 131.08, 144.87, 147.02, 167.53.
Anal. Calculated for C18H20ClN3O4S (MW 409.89): 52.74 (C), 4.92 (H), 10.25 (N). Found: 52.75 (C), 4.92 (H), 10.24 (N).

Data for Compound 3

M.p.: 195 °C.
IR (nujol, cm−1): 1694, 1555, 1375, 1283, 1021.
1H-NMR (400 MHz, DMSO-d6) δ (ppm): 0.95 (3H, t, COOCH2CH3, J = 7.0), 2.26 (3H, s, CH3), 3.90 (2H, m, COOCH2CH3), 5.70 (1H, d, pym, J = 2), 7.41 (1H, d, th, J = 4.2), 7.71 (1H, s, NH), 7.77 (1H, d, th, J = 4.2), 9.43 (1H, s, NH).
13C-NMR (400 MHz, DMSO-d6) δ (ppm): 14.87, 18.61, 46.81, 60.14, 95.07, 114.52, 120.14, 125.63, 130.60, 146.18, 150.13, 151.94, 165.84.
Anal. Calculated for C13H13ClN4O3S (MW 340.79): 45.82 (C), 3.85 (H), 16.44 (N). Found: 45.84 (C), 3.84 (H), 16.45 (N).

Supplementary materials

Supplementary File 1Supplementary File 2Supplementary File 3Supplementary File 4


This work has been supported by a grant from the University of Bologna (RFO).


  1. Biginelli, P. Intorno ad uramidi aldeidiche dell’etere acetilacetico. Gazz. Chim. Ital. 1891, 497–500. [Google Scholar]
  2. Suresh; Sandhu, J.S. Past, present and future of the Biginelli reaction: A critical perspective. Arkivoc 2012, i, 66–133. [Google Scholar]
  3. Kastron, V.V.; Vitolin, R.O.; Khanina, E.L.; ya Duburs, G.; Kimenis, A.A. Fluorine-containing derivatives of 1,2,3,4-tetrahydropyrimidine: Synthesis and pharmacological activity. Khim. Farm. Zh. 1987, 21, 948–952. [Google Scholar] [CrossRef]
  4. Trivedi, A.R.; Bhuva, V.R.; Dholariya, B.H.; Dodiya, D.K.; Kataria, V.B.; Shah, V.H. Novel dihydropyrimidines as a potential new class of antitubercular agents. Bioorg. Med. Chem. Lett. 2010, 20, 6100–6102. [Google Scholar] [CrossRef] [PubMed]
  5. Budriesi, R.; Ioan, P.; Locatelli, A.; Leoni, A.; Cosconati, S.; di Toro, R.; Chiarini, A.; Spampinato, S.; Marinelli, L.; Novellino, E.; et al. Imidazo[2,1-b]thiazole system: A scaffold endowning dihydropyridines with selective cardiopressant activity. J. Med. Chem. 2008, 51, 1592–1600. [Google Scholar] [CrossRef] [PubMed]
  6. Ranu, B.C.; Hajra, A.; Dey, S.S. A practical and green approach towards synthesis of Dihydropyrimidinones without any solvent or catalyst. Org. Process Res. Dev. 2002, 6, 817–818. [Google Scholar] [CrossRef]
  7. Andreani, A.; Rambaldi, M.; Locatelli, A.; Andreani, F. 5-Formylimidazo[2,1-b]thiazoles and derivatives with herbidal acivity. Collect. Czech. Chem. Commun. 1991, 56, 2436–2437. [Google Scholar] [CrossRef]
Back to TopTop